In this piece, we will discuss the 10 Stocks Under $5 That Will Explode.
Recent market analyses justify a selective approach while considering the best penny stocks, especially those in the small and mid-cap space.
On April 8, 2026, in an interview with Reuters, Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company, discussed his inclination toward small- and mid-cap U.S. stocks due to their cyclical exposure, improving earnings estimates, and sizable valuation gaps relative to U.S. large-cap stocks.
These factors are especially relevant considering today’s market environment, which is influenced by growing geopolitical uncertainty, changing rate expectations, and rising energy prices.
He argued that energy stocks were often seen as a protective hedge against prevailing uncertainty; therefore, such stocks may suffer if the current situation ends. However, he highlighted that it was too early to consider removing this hedge completely, given the current sector-neutral position on energy stocks. Moreover, Stucky pointed out that the 10-year interest rate had recently risen from the high-3% range to 4.40%, raising the possibility that higher energy prices and rates could weigh on economic activity and profits.
With this backdrop, let’s turn to our list of the best penny stocks set to explode.
Source:Pixabay
Methodology
To curate our list of stocks under $5 that will explode, we began by screening U.S.-listed companies with potential upside exceeding 50% as of April 8, 2026. This list was narrowed to companies with significant analyst coverage and positive 1-year revenue and earnings growth estimates.
Additionally, we assessed hedge fund sentiment surrounding these stocks using Insider Monkey’s hedge fund database, which tracks over 1,000 hedge funds as of Q4 2025. Finally, we ranked these stocks in ascending order based on their upside potential.
Note: Data is as of April 8, 2026.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Nuvation Bio Inc. (NYSE:NUVB)
Nuvation Bio Inc. (NYSE:NUVB) secures a spot on our list of the best penny stocks set to explode.
As of April 8, 2026, over 90% of covering analysts maintain their “Buy” ratings for Nuvation Bio Inc. (NYSE:NUVB), and the consensus price target of $12 implies an upside of 166.08%.
On April 2, 2026, Wedbush maintained its “Buy” rating and $11 price target, providing a favorable backdrop as Nuvation Bio Inc. (NYSE:NUVB) expanded its strategic reach the day before.
On April 1, 2026, Nuvation Bio Inc. (NYSE:NUVB) added Japan rights to its exclusive license deal with Daiichi Sankyo. This would grant the company the sole right to develop and market safusidenib worldwide.
This development strengthens Nuvation Bio Inc. (NYSE:NUVB)’s capacity to support further publication and regulatory development in IDH1-mutant glioma by enabling the ongoing Phase 3 SIGMA study to extend into Japan and providing access to all current and future data. As a maintenance treatment for high-risk astrocytoma, safusidenib, an oral selective mutant IDH1 inhibitor, has demonstrated encouraging efficacy, including long-lasting responses and extended progression-free survival in Phase 1 and 2 trials.
Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The company was founded by David Hung in 2018, and its headquarters are in New York City.
9. Genius Sports Limited (NYSE:GENI)
Genius Sports Limited (NYSE:GENI) secures a spot on our list of the best penny stocks set to explode.
As of April 8, 2026, 89% of covering analysts remain bullish toward Genius Sports Limited (NYSE:GENI), with the consensus price target of $11.50 implying a 171.87% upside.
As of April 7, 2026, the stock has declined by over 43% in the past year, now closing at a new 52-week low of $4.18. The stock is down over 60% year-to-date.
Earlier, on April 2, 2026, Citi reduced its price target for Genius Sports Limited (NYSE:GENI) from $11 to $9 and assigned a “Buy” rating to the stock. The revision appeared amid the company’s continuous expansion of its ad-tech ambitions.
Meanwhile, on March 27, 2026, Genius Sports Limited (NYSE:GENI) announced fresh partnerships with DirecTV Advertising, Equativ, FreeWheel, Index Exchange, Magnite, OpenX, PubMatic, and The Weather Company. These partnerships will enable integration of Moment Engine across partners that collectively represent 90% of the programmatic advertising ecosystem.
This development came as the company sought to expand distribution for its Moment Engine platform. The platform has been designed to target advertisements around particular in-game moments in real time using live sports and fan-engagement data. According to Genius Sports Limited (NYSE:GENI), this platform is currently accessible on connected TV, online video, and display, with plans to expand to Meta platforms in Q2.
Genius Sports Limited (NYSE:GENI), based in London, U.K., and founded in 2000, offers scalable technology solutions for media, sports, and sports betting. These products include platforms for fan interaction, live data, odds management, and risk services.
8. CytomX Therapeutics, Inc. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX) earns a spot on our list of the best penny stocks set to explode.
As of April 8, 2026, all covering analysts rate CytomX Therapeutics, Inc. (NASDAQ:CTMX) as a “Buy,” with the consensus price target of $12 indicating a 179.07% upside.
In addition to pre-funded warrants for 1,179,245 shares issued to specific investors in place of common stock, CytomX priced an underwritten public offering of 45,990,567 common shares at $5.30 each on March 17, 2026.
The agreement was scheduled to close on March 19, 2026, subject to customary conditions, with CytomX Therapeutics, Inc. (NASDAQ:CTMX) expected to generate roughly $250 million in gross proceeds before discounts and expenses. Furthermore, underwriters were given a 30-day option by the company to purchase up to 7,075,471 more shares.
According to CytomX Therapeutics, Inc. (NASDAQ:CTMX), the proceeds will be used for working capital, capital expenditures, general corporate purposes, and the development of Varseta-M and other pipeline programs.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) has more flexibility moving forward with its clinical program following the raised financing.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) develops conditionally activated biologics targeting the tumor microenvironment, including antibody-drug conjugates, T-cell engagers, immune modulators, and its PROBODY platform for oncology and preclinical applications.
7. Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO) secured a spot on our list of the best penny stocks set to explode.
As of April 8, 2026, analyst sentiment toward Allogene Therapeutics, Inc. (NASDAQ:ALLO) remains bullish, with 85% of analysts issuing “Buy” ratings on the stock. The consensus price target of $7.50 implies an upside of 186.26%.
On March 13, 2026, Piper Sandler increased its price target from $7 to $8 and kept an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO). The firm stated that investor attention was shifting to the April interim analysis from the ALPHA3 study in first-line consolidation LBCL, while noting a favorable setup for cema-cel to achieve a 25%–30% MRD clearance advantage over observation.
This development followed Allogene Therapeutics, Inc. (NASDAQ:ALLO)’s March 12, 2026, Q4 and full-year 2025 results, in which management referred to ALPHA3 as a significant turning point, while also noting that the study may determine whether allogeneic CAR-T can be administered at a biologic-like scale and grow beyond academic centers.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) has $258.3 million in cash, cash equivalents, and investments at the end of 2025, extending the company’s runway into Q1 2028, while guiding to $150 million in operating cash expenses in 2026. Net loss for the fourth quarter was $38.8 million ($0.17 per share) versus a full-year net loss of $190.9 million, or $0.87 per share.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.
6. Repay Holdings Corporation (NASDAQ:RPAY)
Repay Holdings Corporation (NASDAQ:RPAY) is included in our list of the best penny stocks set to explode.
As of April 6, 2026, 71% of covering analysts rate Repay Holdings Corporation (NASDAQ:RPAY) as a “Buy”, with a $7 consensus price target on the stock, implying an upside of 171.84%.
A $372 million all-cash transaction to acquire KUBRA Data Transfer was announced by Repay Holdings Corporation (NASDAQ:RPAY) on March 30, 2026. With this, the company aims to increase its scale in bill payments and customer interactions.
With over $548 million in revenue and $178 million in adjusted EBITDA in 2025, the combined company is anticipated to process over $130 billion in yearly payments.
Repay Holdings Corporation (NASDAQ:RPAY) expects the combined entity to generate $15 million or more in annual run-rate cost synergies, $5 million or more in technology savings over a three-year period, and $5 million or more in revenue potential by 2028.
By 2028, Repay Holdings Corporation (NASDAQ:RPAY) anticipates a 25% increase in free cash flow, and within 18 months, leverage at closing is expected to drop from 4x to less than 3x. The transaction is anticipated to close in Q2 2026 and is supported by a $500 million term loan, including a $100 million undrawn revolver.
Repay Holdings Corporation (NASDAQ:RPAY) is a payment technology company offering integrated solutions that enable businesses to accept and send electronic payments, serving sectors such as personal loans, auto finance, and B2B through its Consumer and Business Payments segments.
While we acknowledge the potential of RPAY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RPAY and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Stocks Under $5 That Will Explode.
Disclosure: None. Follow Insider Monkey on Google News.
